risk of pancreatitis with tirzepatide Fatal, Fulminant, Necrotizing Associated Recent Initiation A Probable Case of Tirzepatide-Induced

10.1002/hep.20538 Hepatology 117 SchmidtC.BladtF.GoedeckeS.BrinkmannV.ZschiescheW.SharpeM.et al (1995)

Common: may affect up to 1 in 10 people feeling dizzy upset stomach or indigestion burping gas (flatulence) bloating of the stomach inflamed stomach (gastritis) the signs include stomach ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn also called gastro-oesophageal reflux disease gallstones hair loss injection site reactions low blood sugar (hypoglycaemia) in patients with diabetes

Bantle JP, et al

Maximum LDL-C reduction occurred by 2 weeks after a single-dose of 140 mg of evolocumab and by 3 weeks after a single-dose of 420 mg of evolocumab